Table 2 Distribution of first line treatment in platinum-eligible patients with R/M SCCHN (%)
|  | Overall (n = 577) | France (n = 114) | Germany (n = 117) | Italy (n = 130) | Spain (n = 117) | UK(n = 99) |
|---|---|---|---|---|---|---|
EXTREME | 52 | 64 | 45 | 38 | 55 | 61 |
Cetuximab based | 9 | 10 | 7 | 15 | 11 | 3 |
Platinum monotherapy | 3 | 1 | 8 | 3 | 4 | 0 |
Platinum plus taxane (+/− other) | 19 | 19 | 20 | 26 | 17 | 9 |
Platinum plus other (excluding taxane) | 13 | 2 | 14 | 16 | 10 | 24 |
Immunotherapy | 3 | 4 | 6 | 1 | 2 | 3 |
Other | 1 | 0 | 1 | 1 | 1 | 0 |